Lupus (SLE) trials in China

In China 163 Also abroad 354

163 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou, Zhengzhou
Age
5 years to 17 years
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
Phase 2Taking people
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
Where
Beijing, Shanghai
Age
18 years to 65 years
People
248
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07299422
Phase 1Taking people
F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus
Where
Shanghai
Age
18 years to 65 years
People
64
Run by
Shandong New Time Pharmaceutical Co., LTD
See details and how to joinNCT07829614
Early phase 1Not yet taking people in China
SNC116 Therapy for Refractory Systemic Lupus Erythematosus
Where
Nanjing
Age
18 years to 65 years
People
28
Run by
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07748156
Phase 2Taking people
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
Where
Beijing, Changchun, Changzhi, Changzhou, Chengdu, Chongqing, Dalian, Ganzhou, Guangzhou, Guilin, Harbin, Huzhou, Jingzhou, Jining, Kunming, Langfang, Lanzhou, Linfen, Luoyang, Nanning, Pingxiang, Shenzhen, Shijiazhuang, Shiyan, Suzhou, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Yangzhou, Yichang, Yichun, Zhengzhou, Zhuzhou
Age
18 years to 70 years
People
120
Run by
Hangzhou Sumgen Biotech Co., Ltd.
See details and how to joinNCT07447986
No phaseTaking people
High Quality Evidence of Chinese Lupus Nephritis (HELP)
Where
Guangzhou
Age
14 years and over
People
5,000
Run by
Sun Yat-sen University
See details and how to joinNCT03001973
Phase 2/3Not yet taking people in China
Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus
Where
Beijing
Age
18 years and over
People
294
Run by
Chinese SLE Treatment And Research Group
See details and how to joinNCT07814664
Phase 1Taking people
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
Where
Beijing, Changsha, Chengdu, Guangzhou, Luoyang, Nanchang, Shanghai, Shenyang, Taiyuan, Tianjin, Xi'an, Zhengzhou
Age
18 years to 75 years
People
47
Run by
Candid Therapeutics
See details and how to joinNCT07215663
No phaseTaking people
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Where
Guangzhou, Hong Kong, Shenzhen, Zhongshan, Zhuhai
Age
18 years and over
People
200 worldwide
Run by
AstraZeneca
See details and how to joinNCT06314282
No phaseTaking people
IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)
Where
Beijing
Age
18 years to 65 years
People
6
Run by
Peking University Third Hospital
See details and how to joinNCT06513429
Phase 3Not yet taking people in China
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
Where
Beijing, Fuzhou, Guangzhou, Harbin, Luzhou, Nanchang, Nanjing, Shenyang, Tianjin, Ürümqi, Xi'an, Xuzhou, Yantai
Age
18 years to 65 years
People
70
Run by
Zhao Minghui
See details and how to joinNCT07767188
Early phase 1Taking people
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
Where
Hangzhou
Age
18 years and over
People
36
Run by
Zhejiang University
See details and how to joinNCT06711146
Phase 2Taking people
A Study of E6742 in Participants With Systemic Lupus Erythematosus
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Jiujiang, Kunming, Linfen, Luoyang, Nanchang, Nanjing, Nanning, Pingxiang, Shantou, Suzhou, Taiyuan, Xinxiang, Yichang, Yinchuan
Age
18 years to 75 years
People
256 worldwide
Run by
Eisai Co., Ltd.
See details and how to joinNCT07515014
Phase 1Taking people
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
Where
Hefei
Age
18 years to 69 years
People
30
Run by
Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT06801119
Phase 1Not yet taking people in China
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
Where
Hefei
Age
18 years to 69 years
People
12
Run by
Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT07523282
Phase 2Not yet taking people in China
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
Where
Changde, Changsha, Guilin, Handan, Huzhou, Jinhua, Linfen, Liupanshui, Loudi, Mianyang, Nanchong, Ningbo, Shanghai, Shenzhen, Shijiazhuang, Xuzhou, Zhongshan, Zhuzhou, Zibo
Age
18 years to 75 years
People
40
Run by
Shanghai Escugen Biotechnology Co., Ltd
See details and how to joinNCT07760155
Phase 1Taking people
IASO-782 in Systemic Lupus Erythematosus
Where
Hangzhou, Huzhou, Jiaxing
Age
18 years to 75 years
People
20
Run by
Shanghai IASO Biotechnology Co., Ltd
See details and how to joinNCT07483346
Phase 1Not yet taking people in China
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
Where
Chengdu
Age
18 years to 65 years
People
64
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07751315
Phase 1/2Taking people
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Where
Beijing
Age
10 years to 65 years
People
45
Run by
Beijing GoBroad Hospital
See details and how to joinNCT06947460
Phase 4Taking people
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
Where
Beijing, Changchun, Changsha, Chongqing, Nanjing, Shanghai, Shenzhen
Age
6 years to 18 years
People
198
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07719140
Early phase 1Not yet taking people in China
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
Where
Shanghai
Age
18 years to 70 years
People
30
Run by
Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07596680
No phaseNot yet taking people in China
Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis
Where
Nanjing
Age
18 years and over
People
50
Run by
Nanjing University
See details and how to joinNCT07706998
Phase 1Taking people
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
Where
Shanghai
Age
18 years to 75 years
People
84
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06857214
Phase 2Taking people
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
Where
Anyang, Beijing, Bengbu, Bozhou, Changchun, Changsha, Chongqing, Daqing, Guangzhou, Hangzhou, Jiangmen, Jingzhou, Lanzhou, Linfen, Nanchang, Nanjing, Nanning, Puyang, Shanghai, Shenzhen, Taizhou, Tianjin, Weifang, Wuhan, Xi’an, Xuchang, Yibin, Yichang, Zhengzhou, Zhuzhou, Zunyi
Age
18 years to 74 years
People
198
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07509892
Phase 1Taking people
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
Where
Nanjing
Age
18 years to 65 years
People
24
Run by
Nanjing University School of Medicine
See details and how to joinNCT06285279